-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Named to the 2024 China Pharmaceutical Market Top 100 List
Category:
发布时间：2025-03-31
【概要描述】
On March 28, at the “MDS 2025 Second Pharmaceutical Marketing Big Data Summit,” Yaozhi Network, in collaboration with the Organizing Committee of the Greater Health Industry (Chongqing) Expo and the Dual-Product Fair, officially unveiled the “2024 China Pharmaceutical Market Pharmaceutical Company Rankings.” Shijiazhuang Sihua Pharmaceutical Group was honored on two key lists within the 2024 rankings: it ranked 55th on the Overall Top 100 list and 32nd on the Chemical Pharmaceuticals Top 100 list.
On March 28, at the “MDS 2025 Second Pharmaceutical Marketing Big Data Summit,” Yaozhi Network, in collaboration with the Organizing Committee of the Greater Health Industry (Chongqing) Expo and the Dual-Product Fair, proudly unveiled the “2024 China Pharmaceutical Market Pharmaceutical Company Rankings.” Shijiazhuang Sihua Pharmaceutical Group was featured on two key lists in the 2024 rankings: it ranked 55th on the Top 100 list and 32nd on the Top 100 list for chemical pharmaceuticals.
According to available information, the “2024 China Pharmaceutical Market Ranking of Pharmaceutical Companies” is divided into two categories: the Corporate Ranking and the Pharmaceutical Brand Ranking. The data for these rankings are sourced from the Yaozhi Pharmaceutical Sales Database, reflecting the sales performance of companies in public medical institutions, offline pharmacies, and online pharmacies, as well as the sales strength of individual pharmaceutical brands for the year 2024. Having been published consecutively for two years, this ranking provides an authoritative analysis of the structural transformation and evolving competitive landscape of the pharmaceutical industry.
In recent years, the Group has proactively built an innovative, high-value ecosystem, focusing on key therapeutic areas such as anti-infectives, respiratory diseases, neurological disorders, cardiovascular and cerebrovascular conditions, gastroenterology, anesthesia, dialysis, endocrinology, and oncology. The Group has continuously advanced integrated “API–formulation” development, accelerated research and development of high-end, complex generic drugs, innovative medicines, and specialty APIs, and promoted the synchronized advancement of the entire drug R&D–market translation value chain, thereby establishing a distinctive product portfolio and competitive edge in the industry. In 2024, driven by iterative product innovation and sustained accumulation, the Group secured approval for 82 new products, placing it among the leaders in the industry in terms of both submissions and approvals. Since the beginning of this year, the Group has consecutively obtained approval for 18 new products, bringing the total number of approved and evaluated products to 122 varieties across 162 specifications, which has effectively propelled the company’s accelerated growth.
A spokesperson for the group stated that it will regard the research, development, and production of more “Chinese medicines” as its core mission, continuously streamline and optimize its product pipeline, actively align with the new development paradigm of the pharmaceutical industry, foster and cultivate new drivers of productivity, accelerate the pace of product R&D and commercialization, and strive to inject additional engines and momentum into the high-quality development of both the company and Shijiazhuang’s biopharmaceutical industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091